- Home
- Publications
- Publication Search
- Publication Details
Title
Antibodies to watch in 2020
Authors
Keywords
-
Journal
mAbs
Volume 12, Issue 1, Pages 1703531
Publisher
Informa UK Limited
Online
2019-12-18
DOI
10.1080/19420862.2019.1703531
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Fab Fragment of VHH-Based Antibody Netakimab: Crystal Structure and Modeling Interaction with Cytokine IL-17A
- (2019) Olga Kostareva et al. Crystals
- Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease
- (2019) Charlotte Lichnog et al. Frontiers in Pharmacology
- The Mechanism Of Action Of The Anti-CD38 Monoclonal Antibody Isatuximab In Multiple Myelmoa
- (2019) Laura Moreno et al. CLINICAL CANCER RESEARCH
- HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
- (2019) Pravin U. Dugel et al. OPHTHALMOLOGY
- Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee
- (2019) Thomas J. Schnitzer et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.
- (2019) Daniel Peter Petrylak et al. JOURNAL OF CLINICAL ONCOLOGY
- Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
- (2019) Kristian Reich et al. LANCET
- Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan
- (2019) David M. Goldenberg et al. mAbs
- An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
- (2019) Kevan C. Herold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small Cell Lung Cancer: Results From the Phase II TRINITY Study
- (2019) Daniel Morgensztern et al. CLINICAL CANCER RESEARCH
- Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
- (2019) Bruce A C Cree et al. LANCET
- Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
- (2019) Takashi Yamamura et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
- (2019) Sabue Mulangu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates
- (2018) Kristen E Pascal et al. JOURNAL OF INFECTIOUS DISEASES
- Antibodies to watch in 2018
- (2018) Hélène Kaplon et al. mAbs
- Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
- (2018) Joseph W. Arndt et al. Scientific Reports
- Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
- (2018) Kenneth B Gordon et al. LANCET
- Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis
- (2018) Abdullah Kutlar et al. AMERICAN JOURNAL OF HEMATOLOGY
- Antibodies to watch in 2019
- (2018) Hélène Kaplon et al. mAbs
- Teprotumumab for Thyroid-Associated Ophthalmopathy
- (2017) Terry J. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibodies to watch in 2017
- (2016) Janice M. Reichert mAbs
- Antibodies to watch in 2016
- (2015) Janice M. Reichert mAbs
- Antibodies to watch in 2014
- (2014) Janice M Reichert mAbs
- Antibodies to watch in 2015
- (2014) Janice M Reichert mAbs
- The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients
- (2013) C Kellner et al. LEUKEMIA
- Antibodies to watch in 2014
- (2013) Janice M Reichert mAbs
- Which are the antibodies to watch in 2013?
- (2013) Janice M. Reichert mAbs
- Antibodies to watch in 2013
- (2013) Janice M Reichert mAbs
- Retrocyte Display® technology: Generation and screening of a high diversity cellular antibody library
- (2013) Ekaterina Breous-Nystrom et al. METHODS
- Which are the antibodies to watch in 2012?
- (2012) Janice M. Reichert mAbs
- Antibody-based therapeutics to watch in 2011
- (2011) Janice M. Reichert mAbs
- Antibodies to watch in 2010
- (2010) Janice M. Reichert mAbs
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started